IFNG and COVID-19: Another therapeutic strategy that has been proposed to improve antiviral Th1 responses is based on the use of SARS‐CoV‐2‐specific T cells with IFN‐γ exosomes; clinical trial has been registered to test efficacy in COVID‐19 patients (NCT04389385) (Table 1).